Observational Prospective Study on Patients Treated With Norditropin®

Novo Nordisk

Status: Completed

Conditions: Chronic Kidney Disease; Small for Gestational Age; Growth Hormone Deficiency in Children; Genetic Disorder; Turner Syndrome; Adult Growth Hormone Deficiency; Growth Hormone Disorder; Noonan Syndrome; Chronic Renal Insufficiency; Foetal Growth Problem

Treatments: Drug: somatropin

Study type: Observational

Funder types: Industry

Identifiers

NCT00960128

2008-001674-32 (EudraCT Number)

GHLIQUID-3676

Details and patient eligibility

About

This observational study is conducted globally. The aim of the study is to investigate the effectiveness and safety of real-life treatment with Norditropin®. The study population will consist of children and adults who are on treatment with Norditropin® in accordance with normal clinical practice.

Enrollment: 21,249 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Judged by the physician as per the Norditropin® label

Exclusion criteria

• Judged by the physician as per the Norditropin® label

Trial design

21,249 participants in 2 patient groups

A

Description:

Adult cohort

Treatment:

Drug: somatropin

Drug: somatropin

B

Description:

Paediatric cohort

Treatment:

Drug: somatropin

Drug: somatropin